-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
News from April 7, 2021 //---Regulatory T (Treg) cells expressing CD4 and Foxp3 are the main regulators of autoimmune diseases.
However, the temporal and spatial characteristics of tissue-specific autoimmune suppression mediated by Treg cells have not yet been clearly revealed.
In a study recently published in the journal PNAS, Benoît L.
Salomon's team from Sorbonne University in France studied the tumor necrosis factor receptor 2 (TNFR2) signaling in Treg cells during multiple sclerosis (EAE).
The role of this has been further revealed.
The authors found that Treg cells expressing TNFR2 are essential for suppressing the severity of the disease at the peak of EAE, but have no effect on T cell activation in the lymphatic tissues at the initial stage of disease onset.
In terms of mechanism, TNFR2 signaling can maintain functional Treg cells, allowing them to continuously express CTLA-4 and Blimp-1, thereby actively inhibiting the expansion of pathogenic T cells in the inflamed central nervous system.
The treatment of EAE mice with TNF and TNFR2 agonists and antagonists further confirmed the regulatory role of Treg cells in key stages.
However, the temporal and spatial characteristics of tissue-specific autoimmune suppression mediated by Treg cells have not yet been clearly revealed.
In a study recently published in the journal PNAS, Benoît L.
Salomon's team from Sorbonne University in France studied the tumor necrosis factor receptor 2 (TNFR2) signaling in Treg cells during multiple sclerosis (EAE).
The role of this has been further revealed.
The authors found that Treg cells expressing TNFR2 are essential for suppressing the severity of the disease at the peak of EAE, but have no effect on T cell activation in the lymphatic tissues at the initial stage of disease onset.
In terms of mechanism, TNFR2 signaling can maintain functional Treg cells, allowing them to continuously express CTLA-4 and Blimp-1, thereby actively inhibiting the expansion of pathogenic T cells in the inflamed central nervous system.
The treatment of EAE mice with TNF and TNFR2 agonists and antagonists further confirmed the regulatory role of Treg cells in key stages.
(Image source:the author constructed and bred Foxp3-CreTnfrsf1b fl (cKO) mice.
TNFR2 in the Treg cells of cKO mice was specifically knocked out.
By inducing the occurrence of EAE, the authors found that the knockout of TNFR2 would significantly affect the homeostasis of Treg cells and lead to further exacerbation of EAE.
TNFR2 in the Treg cells of cKO mice was specifically knocked out.
By inducing the occurrence of EAE, the authors found that the knockout of TNFR2 would significantly affect the homeostasis of Treg cells and lead to further exacerbation of EAE.
(Figure 1, TNFR2 deficiency in Treg cells can aggravate the severity of EAE disease)
Furthermore, the authors constructed an induced mutant mouse Foxp3Cre-ERT2Tnfrsf1bfl (icKO), which will knock out TNFSFR2 after being induced by tamoxifen.
The author first induced EAE on wild-type and icKO mice, and added tamoxifen to induce induction on day 7-14.
After that, the author studied the number of Tregs and gene expression in the CNS region of wild-type and icKO mice.
The results showed that although there was no significant difference in the number of Treg cells in the CNS region of icKO and wild-type mice, the expression levels of CTLA-4 and Blimp-1 of Treg cells in mutant mice were significantly down-regulated, and their activation levels were also affected.
Had a significant impact.
The author first induced EAE on wild-type and icKO mice, and added tamoxifen to induce induction on day 7-14.
After that, the author studied the number of Tregs and gene expression in the CNS region of wild-type and icKO mice.
The results showed that although there was no significant difference in the number of Treg cells in the CNS region of icKO and wild-type mice, the expression levels of CTLA-4 and Blimp-1 of Treg cells in mutant mice were significantly down-regulated, and their activation levels were also affected.
Had a significant impact.
(Figure 2, TNFR2 deficiency affects the gene expression and activity of Treg cells)
Afterwards, the author analyzed the activation state of conventional T cells (Tconv) in the brain after EAE induction in mice, and the results showed that the defect of TNFR2 in Treg cells would increase the activation level of Tconv and its pathology.
Finally, through T cell transplantation experiments, the authors found that the presence of TNFR2 in Tregs can inhibit the severity of the disease in the late stage of EAE (10 days), and artificially inhibiting the signal of TNFR2 in Tregs by TNF injection can cause disease in mice.
Increased severity and decreased survival rates.
Increased severity and decreased survival rates.
In summary, a series of experimental evidences show that endogenous Treg cells can specifically inhibit autoimmune diseases by acting on target tissues during the development of EAE inflammation.
This discovery is a result of some adverse effects of anti-TNF therapy on patients.
The reaction provides mechanistic insights.
(Bioon.
com)
This discovery is a result of some adverse effects of anti-TNF therapy on patients.
The reaction provides mechanistic insights.
(Bioon.
com)
Original source: Emilie Ronin, Charlotte Pouchy, Maryam Khosravi et al.
, Tissue-restricted control of established central nervous system autoimmunity by TNF receptor 2–expressing Treg cells.
Proceedings of the National Academy of Sciences Mar 2021, 118 (13) e2014043118; DOI: 10.
1073/pnas.
2014043118
, Tissue-restricted control of established central nervous system autoimmunity by TNF receptor 2–expressing Treg cells.
Proceedings of the National Academy of Sciences Mar 2021, 118 (13) e2014043118; DOI: 10.
1073/pnas.
2014043118
(Figure 1, TNFR2 deficiency in Treg cells can aggravate the severity of EAE disease)
Furthermore, the authors constructed an induced mutant mouse Foxp3Cre-ERT2Tnfrsf1bfl (icKO), which will knock out TNFSFR2 after being induced by tamoxifen.
The author first induced EAE on wild-type and icKO mice, and added tamoxifen to induce induction on day 7-14.
After that, the author studied the number of Tregs and gene expression in the CNS region of wild-type and icKO mice.
The results showed that although there was no significant difference in the number of Treg cells in the CNS region of icKO and wild-type mice, the expression levels of CTLA-4 and Blimp-1 of Treg cells in mutant mice were significantly down-regulated, and their activation levels were also affected.
Had a significant impact.
The author first induced EAE on wild-type and icKO mice, and added tamoxifen to induce induction on day 7-14.
After that, the author studied the number of Tregs and gene expression in the CNS region of wild-type and icKO mice.
The results showed that although there was no significant difference in the number of Treg cells in the CNS region of icKO and wild-type mice, the expression levels of CTLA-4 and Blimp-1 of Treg cells in mutant mice were significantly down-regulated, and their activation levels were also affected.
Had a significant impact.
(Figure 2, TNFR2 deficiency affects the gene expression and activity of Treg cells)
Afterwards, the author analyzed the activation state of conventional T cells (Tconv) in the brain after EAE induction in mice, and the results showed that the defect of TNFR2 in Treg cells would increase the activation level of Tconv and its pathology.
Finally, through T cell transplantation experiments, the authors found that the presence of TNFR2 in Tregs can inhibit the severity of the disease in the late stage of EAE (10 days), and artificially inhibiting the signal of TNFR2 in Tregs by TNF injection can cause disease in mice.
Increased severity and decreased survival rates.
Increased severity and decreased survival rates.
In summary, a series of experimental evidences show that endogenous Treg cells can specifically inhibit autoimmune diseases by acting on target tissues during the development of EAE inflammation.
This discovery is a result of some adverse effects of anti-TNF therapy on patients.
The reaction provides mechanistic insights.
(Bioon.
com)
This discovery is a result of some adverse effects of anti-TNF therapy on patients.
The reaction provides mechanistic insights.
(Bioon.
com)
Original source: Emilie Ronin, Charlotte Pouchy, Maryam Khosravi et al.
, Tissue-restricted control of established central nervous system autoimmunity by TNF receptor 2–expressing Treg cells.
Proceedings of the National Academy of Sciences Mar 2021, 118 (13) e2014043118; DOI: 10.
1073/pnas.
2014043118
, Tissue-restricted control of established central nervous system autoimmunity by TNF receptor 2–expressing Treg cells.
Proceedings of the National Academy of Sciences Mar 2021, 118 (13) e2014043118; DOI: 10.
1073/pnas.
2014043118
(Figure 2, TNFR2 deficiency affects the gene expression and activity of Treg cells)
Afterwards, the author analyzed the activation state of conventional T cells (Tconv) in the brain after EAE induction in mice, and the results showed that the defect of TNFR2 in Treg cells would increase the activation level of Tconv and its pathology.
Finally, through T cell transplantation experiments, the authors found that the presence of TNFR2 in Tregs can inhibit the severity of the disease in the late stage of EAE (10 days), and artificially inhibiting the signal of TNFR2 in Tregs by TNF injection can cause disease in mice.
Increased severity and decreased survival rates.
Increased severity and decreased survival rates.
In summary, a series of experimental evidences show that endogenous Treg cells can specifically inhibit autoimmune diseases by acting on target tissues during the development of EAE inflammation.
This discovery is a result of some adverse effects of anti-TNF therapy on patients.
The reaction provides mechanistic insights.
(Bioon.
com)
This discovery is a result of some adverse effects of anti-TNF therapy on patients.
The reaction provides mechanistic insights.
(Bioon.
com)
Original source: Emilie Ronin, Charlotte Pouchy, Maryam Khosravi et al.
, Tissue-restricted control of established central nervous system autoimmunity by TNF receptor 2–expressing Treg cells.
Proceedings of the National Academy of Sciences Mar 2021, 118 (13) e2014043118; DOI: 10.
1073/pnas.
2014043118
, Tissue-restricted control of established central nervous system autoimmunity by TNF receptor 2–expressing Treg cells.
Proceedings of the National Academy of Sciences Mar 2021, 118 (13) e2014043118; DOI: 10.
1073/pnas.
2014043118
Finally, through T cell transplantation experiments, the authors found that the presence of TNFR2 in Tregs can inhibit the severity of the disease in the late stage of EAE (10 days), and artificially inhibiting the signal of TNFR2 in Tregs by TNF injection can cause disease in mice.
Increased severity and decreased survival rates.
Increased severity and decreased survival rates.
In summary, a series of experimental evidences show that endogenous Treg cells can specifically inhibit autoimmune diseases by acting on target tissues during the development of EAE inflammation.
This discovery is a result of some adverse effects of anti-TNF therapy on patients.
The reaction provides mechanistic insights.
(Bioon.
com)
This discovery is a result of some adverse effects of anti-TNF therapy on patients.
The reaction provides mechanistic insights.
(Bioon.
com)
Original source: Emilie Ronin, Charlotte Pouchy, Maryam Khosravi et al.
, Tissue-restricted control of established central nervous system autoimmunity by TNF receptor 2–expressing Treg cells.
Proceedings of the National Academy of Sciences Mar 2021, 118 (13) e2014043118; DOI: 10.
1073/pnas.
2014043118
, Tissue-restricted control of established central nervous system autoimmunity by TNF receptor 2–expressing Treg cells.
Proceedings of the National Academy of Sciences Mar 2021, 118 (13) e2014043118; DOI: 10.
1073/pnas.
2014043118
Finally, through T cell transplantation experiments, the authors found that the presence of TNFR2 in Tregs can inhibit the severity of the disease in the late stage of EAE (10 days), and artificially inhibiting the signal of TNFR2 in Tregs by TNF injection can cause disease in mice.
Increased severity and decreased survival rates.
Increased severity and decreased survival rates.
In summary, a series of experimental evidences show that endogenous Treg cells can specifically inhibit autoimmune diseases by acting on target tissues during the development of EAE inflammation.
This discovery is a result of some adverse effects of anti-TNF therapy on patients.
The reaction provides mechanistic insights.
(Bioon.
com)
This discovery is a result of some adverse effects of anti-TNF therapy on patients.
The reaction provides mechanistic insights.
(Bioon.
com)
Original source: Emilie Ronin, Charlotte Pouchy, Maryam Khosravi et al.
, Tissue-restricted control of established central nervous system autoimmunity by TNF receptor 2–expressing Treg cells.
Proceedings of the National Academy of Sciences Mar 2021, 118 (13) e2014043118; DOI: 10.
1073/pnas.
2014043118
, Tissue-restricted control of established central nervous system autoimmunity by TNF receptor 2–expressing Treg cells.
Proceedings of the National Academy of Sciences Mar 2021, 118 (13) e2014043118; DOI: 10.
1073/pnas.
2014043118
In summary, a series of experimental evidences show that endogenous Treg cells can specifically inhibit autoimmune diseases by acting on target tissues during the development of EAE inflammation.
This discovery is a result of some adverse effects of anti-TNF therapy on patients.
The reaction provides mechanistic insights.
(Bioon.
com)
This discovery is a result of some adverse effects of anti-TNF therapy on patients.
The reaction provides mechanistic insights.
(Bioon.
com)
Original source: Emilie Ronin, Charlotte Pouchy, Maryam Khosravi et al.
, Tissue-restricted control of established central nervous system autoimmunity by TNF receptor 2–expressing Treg cells.
Proceedings of the National Academy of Sciences Mar 2021, 118 (13) e2014043118; DOI: 10.
1073/pnas.
2014043118
, Tissue-restricted control of established central nervous system autoimmunity by TNF receptor 2–expressing Treg cells.
Proceedings of the National Academy of Sciences Mar 2021, 118 (13) e2014043118; DOI: 10.
1073/pnas.
2014043118
Original source: Emilie Ronin, Charlotte Pouchy, Maryam Khosravi et al.
, Tissue-restricted control of established central nervous system autoimmunity by TNF receptor 2–expressing Treg cells.
Proceedings of the National Academy of Sciences Mar 2021, 118 (13) e2014043118; DOI: 10.
1073/pnas.
2014043118
Original source: Tissue-restricted control of established central nervous system autoimmunity by TNF receptor 2–expressing Treg cells. , Tissue-restricted control of established central nervous system autoimmunity by TNF receptor 2–expressing Treg cells.
Proceedings of the National Academy of Sciences Mar 2021, 118 (13) e2014043118; DOI: 10.
1073/pnas.
2014043118
Proceedings of the National Academy of Sciences
